Trial reportPapillomavirus research (Amsterdam, Netherlands)2020
Prevalence, incidence, and natural history of HPV infection in adult women ages 24 to 45 participating in a vaccine trial.
Trial report in Papillomavirus research (Amsterdam, Netherlands), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 3 syntheses or guidelines pooled it, 50 citations in OpenAlex.
- HPV vaccination efficacy in primary and tertiary prevention of vulvar and vaginal HPV-related high grade dysplasia and cancers: A systematic review.Human vaccines & immunotherapeutics · 2025Pooled it
- Human papillomavirus (HPV) vaccination for the prevention of cervical cancer and other HPV-related diseases: a network meta-analysis.The Cochrane database of systematic reviews · 2025Pooled it
- The pattern of human papillomavirus infection and genotypes among Nigerian women from 1999 to 2019: a systematic review.Annals of medicine · 2021Pooled it
- Trial
- Estimating the age distribution of disease-causal HPV infection in women with high-grade cervical intraepithelial neoplasia in Denmark, Estonia, Norway, Slovenia, and Sweden: A modeling study.Human vaccines & immunotherapeutics · 2026Article
- Economic and epidemiological burden of HPV-related diseases in the Czech Republic: A claims database analysis.Human vaccines & immunotherapeutics · 2026Article
- Age of acquisition of disease-causal human papillomavirus infection to high-grade cervical intraepithelial neoplasia (CIN2+) in England.BMC infectious diseases · 2026Article
- Prevalence and genotype distribution of high-risk human papillomavirus infections among women in selected communities in the Philippines: Results of the defeat HPV study.Journal of virus eradication · 2026Article
- Article
- Vaccine-preventable HPV burden and cervical abnormalities in women during 2022-2024 Octobre Rose campaigns in Libreville.Nature communications · 2025Article
- Unveiling the burden of human papillomavirus infection and risk factors among Indigenous women in Mizoram, Northeast India.BMC infectious diseases · 2025Article
- Epidemiological analysis of human papillomavirus infection in senior women: a hospital-based retrospective study.BMC infectious diseases · 2025Article
- A review of the carcinogenic potential of human papillomavirus (HPV) in urological cancers.Virology journal · 2025Review
- Lives Saved Through Increasing Adherence to Follow-Up After Abnormal Cervical Cancer Screening Results.O&G open · 2024Article
- High rate of non-vaccine targeted high-risk HPV genotypes circulate among women in Eastern Ethiopia.Scientific reports · 2024Article
- Frequency ofIranian journal of pathology · 2024Article
- Cost-effectiveness of p16/Ki-67 Dual-Stained Cytology Reflex Following Co-testing with hrHPV Genotyping for Cervical Cancer Screening.Cancer prevention research (Philadelphia, Pa.) · 2023Article
- High-risk HPV prevalence and genotype distribution among women in Liaocheng, Shandong Province, China from 2016 to 2022.Frontiers in public health · 2023Article
- Burden of CIN2+ diagnoses and conizations in women aged 18-45 years-a retrospective secondary data analysis of German statutory health insurance claims data.Archives of gynecology and obstetrics · 2022Article
- The influence of men on HPV vaccination of their spouse/partner in China.Human vaccines & immunotherapeutics · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 8 institutions in 4 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesThe natural history of human papillomavirus (HPV) infection has been studied extensively in young women; this study investigated HPV infection in adult women.
methodsData from 3817 women aged 24-45 years in a global trial of the 4-valent HPV (6/11/16/18) vaccine were used to calculate prevalence of anogenital infections containing 9-valent (9v) HPV vaccine types (6/11/16/18/31/33/45/52/58) and five non-vaccine types (35/39/51/56/59). Incidence of infections and persistent infections was estimated for 989 placebo recipients naive to all 14 HPV types at baseline. Age-adjusted hazard ratios were calculated for various sociodemographic factors.
resultsPrevalence of anogenital infection was highest in France at 29.2% (9vHPV types) and 21.7% (non-vaccine types) and lowest in the Philippines at 7.6% (9vHPV types) and 5.1% (non-vaccine types). Overall, HPV incidence (per 100 person-years) was 5.2 (9vHPV types) and 4.7 (non-vaccine types), and incidence of persistent infection was 2.7 (9vHPV types) and 2.1 (non-vaccine types). Factors associated with new HPV infections included younger age, younger age at first intercourse, being single, current use of tobacco, and higher number of past and recent sex partners.
conclusionsBecause mid-adult women acquire new HPV infections, administration of the 9vHPV vaccine could reduce HPV-related morbidity and mortality in this population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.